Amyloid Adjacent to Tumors
Amyloid adjacent to tumors is a localized, secondary form of amyloid deposition that develops in the stroma surrounding, or sometimes within, benign and malignant skin tumors.
Unlike systemic amyloidosis or the stand-alone forms of primary cutaneous amyloidosis (PCA), amyloid found in this setting is not a disease in its own right. It is an incidental histopathological finding.
Recognizing it still matters clinically. It keeps the pathologist from mistaking it for the more serious nodular amyloidosis, and it offers insight into the stromal reaction within the tumor microenvironment.
Pathophysiology and Origin of the Amyloid Fibrils
How amyloid forms around a skin tumor depends on the nature of the underlying tumor cells. In this setting the amyloid comes from two main biochemical sources:
- Cytokeratin-derived (amyloid K):
- Most often seen with tumors of epidermal origin, such as basal cell carcinoma (BCC), actinic keratosis and seborrheic keratosis.
- Tumor cells or abnormal keratinocytes undergo apoptosis or degenerate and break down. The released cytokeratin filaments enter the stroma, where enzymes refold them into beta-pleated sheets, forming amyloid K.
- Immunoglobulin light chain-derived (amyloid AL):
- Typically found in tumors with a dense chronic inflammatory infiltrate, vascular tumors or glandular tumors.
- The tumor microenvironment draws in plasma cells, which secrete kappa or lambda light chains. These accumulate locally as amyloid AL along the edge of the tumor.
Skin Tumors Commonly Associated With Amyloid Deposits
Peritumoral amyloid can appear in a wide range of skin lesions, whether benign, precancerous or malignant:
- Basal cell carcinoma (BCC):
- The skin tumor most frequently accompanied by amyloid, found in 10–75% of BCC biopsy specimens depending on the staining technique.
- The amyloid usually sits in the fibrous stroma right next to the basaloid tumor islands, or in the center of the islands themselves.
- Squamous cell carcinoma (SCC) and actinic keratosis: Necrosis and keratin degeneration of atypical squamous cells release large amounts of cytokeratin, which forms patchy amyloid in the dermal papillae.
- Benign epidermal and adnexal tumors: seborrheic keratosis, dermatofibroma, syringoma, poroma and angiofibroma.
- Vascular and neural lesions: hemangioma and nerve sheath tumors (schwannoma, neurofibroma).
Differential Diagnosis and Histopathological Significance
Histopathological Features
- Routine H&E staining: Amorphous, homogeneous, pale pink (eosinophilic) masses scattered through the connective tissue at the tumor margin.
- Congo red staining: The deposits stain brick red. Under polarized light they show apple-green birefringence, which confirms that the material is amyloid.
Clinical and Prognostic Comparison
| Feature | Amyloid Adjacent to Tumors | Primary Nodular Amyloidosis |
|---|---|---|
| Nature | Secondary phenomenon in the tumor stroma | Primary plasma cell infiltrative disorder |
| Clinical detection | Usually invisible to the eye; found on biopsy | Clearly visible yellow-pink nodule or plaque on the skin |
| Histopathology | Small amyloid deposits surrounding tumor cells (BCC, SK, etc.) | Large AL amyloid masses infiltrating the dermis and subcutis |
| Prognosis | Depends entirely on the underlying tumor | 7–15% progress to systemic AL amyloidosis |
| Management | Definitive treatment of the primary tumor (BCC, SCC, etc.) | Bone marrow, cardiac and renal screening plus surgical excision of the nodule |
Our Treatment Approach at Haute-Derma
Because peritumoral amyloid is simply an accompanying histological feature, the amyloid itself does not need any specific treatment.
- Focus on treating the primary tumor:
- For basal cell or squamous cell carcinoma: excision with safe margins (or Mohs surgery), followed by reconstruction. Once the tumor is completely removed, amyloid formation stops as well.
- For benign growths (seborrheic keratosis, dermatofibroma, etc.): CO2 laser, electrocautery or cosmetic surgery, depending on what the patient wants.
- No long-term systemic screening needed: Unlike nodular amyloidosis, which calls for serum protein electrophoresis (SPEP), serum free light chains (sFLC) and echocardiography, amyloid adjacent to tumors is a local phenomenon and is not associated with progression to systemic amyloidosis. Your doctor can explain this so you can feel reassured.
